- Research Article
- 10.1186/s12913-026-14095-z
Just culture and restorative just culture in healthcare settings: a scoping review of interventions, activities, factors and outcomes.
- Jan 29, 2026
- BMC health services research
- Kristina Brown + 12 more +12
Publications from 2021 to 2026
Showing 10 of 107 papers
Just culture and restorative just culture in healthcare settings: a scoping review of interventions, activities, factors and outcomes.
Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis
Efficacious and well-tolerated systemic, oral treatments for psoriasis are needed. We report preclinical and phase 1c (NCT06808815) results for DC-806, a small molecule interleukin (IL)-17 inhibitor, for the treatment of mild-to-moderate psoriasis. Preclinical results demonstrated DC-806 targets IL-17AA and IL-17AF with secukinumab-like therapeutic efficacy. In the phase 1c trial, 32 patients consented to receive twice daily (BID) doses of placebo or DC-806 (200 mg or 800 mg) for 28 days. No serious adverse events (SAEs) or discontinuations due to treatment-related adverse events (TRAEs) occurred. In an exploratory analysis, adjusted mean percentage reductions from baseline in psoriasis area and severity indices (PASI) at Day 29 were 43.7%, 15.1%, and 13.3% for 800 mg BID, 200 mg BID, and placebo arms, respectively (800 mg BID vs placebo, P value = 0.0008). DC-806 was found to be well tolerated with an acceptable safety profile and preliminary signals of clinical efficacy in mild-to-moderate psoriasis. EudraCT Identifier: 2021-002888-21.
Read moreSputum Cytokine Repeatability in COPD
IntroductionSputum biomarker measurements are used to measure airway inflammation in COPD patients. We have previously validated a Luminex assay able to quantify 15 analytes in COPD sputum supernatant. This assay demonstrated sputum protein expression profiles associated with neutrophilia, airway bacterial colonisation and current smoking in COPD.MethodsWe report repeat sputum supernatant analysis at 6 months from a sub-group of COPD patients who participated in the original study. 48 COPD patients provided a repeat sputum sample at 6 months. 15 panel analytes were detectable.ResultsRepeated sputum cytokine measurements showed a significant positive correlation between baseline and 6 months for all analytes except IL-1RA with intraclass correlation coefficient (ICC) indicating good to excellent repeatability. IL-1β, IL-2, IL-8, IL-17A, G-CSF, MIP-1α, MIP-1β and TNF-α were significantly correlated with sputum neutrophil percentage at 6 months. IL-1β, IL-4, IL-8 and G-CSF were significantly increased in Haemophilus influenzae colonised patients and IL-1β, IL-4, IL-8, G-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β and TNF-α were significantly higher in ex-smoking COPD patients.DiscussionA multiplex immunoassay used at repeated visits in COPD patients showed a high degree of reproducibility for the majority of analytes. There were reproducible inflammatory signatures in sputum associated with clinical characteristics in COPD patients.
Read moreBiological Therapy in COPD Management: Current Evidence, Challenges and Opportunities.
The goals of COPD treatment are to improve symptoms and decrease future risks such as exacerbations, lung function decline and mortality. Despite receiving maximal inhaled treatment, many COPD patients continue to exacerbate. This highlights the need for novel therapeutic approaches. There is now positive clinical trial data supporting the use of monoclonal antibody treatments in COPD. There remain challenges to define responder populations for each monoclonal antibody class on the basis of clinical characteristics and biomarkers. There are considerable future opportunities, including the targeting of disease activity with monoclonal antibodies at earlier stages in the natural history of COPD in order to slow the rate of disease progression. Using monoclonal antibodies during an exacerbation as a targeted treatment also hold potential. Monoclonal antibody treatments have the potential to change the landscape of COPD management.
Read moreClinical Remission in Patients with Asthma treated with Triple Inhalation Therapy: Post-hoc Evaluation of TRIMARAN and TRIGGER RCTs
<bold>Background:</bold> On-treatment clinical remission is a concept adopted in severe asthma, particularly with biologics. However, remission with inhaled therapy remains underexplored. This post-hoc pooled analysis of TRIMARAN (<ext-link>NCT02676076</ext-link>) and TRIGGER (<ext-link>NCT02676089</ext-link>) evaluates remission in patients treated with beclomethasone/formoterol/glycopyrronium (BDP/FF/G) vs. beclomethasone/formoterol (BDP/FF). <bold>Methods:</bold> Patients from TRIMARAN and TRIGGER were categorized based on complete and partial remission criteria over the 52 weeks of treatment. Complete remission was defined as: 1)no oral corticosteroid (OCS) use; 2)no severe exacerbations; 3)Asthma Control Questionnaire (ACQ-5) score <1.5 in the last 6 months of treatment; and 4)pre-dose FEV1 at Week 52 ≥ baseline. Partial remission required no OCS use plus 2 of the other 3 criteria. Odds ratios (OR) and p-values were derived from logistic regression. <bold>Results:</bold> Among 2291 patients (BDP/FF=1145; BDP/FF/G=1146), complete remission was achieved by 338 patients (29.49%) with BDP/FF/G vs. 260 patients (22.71%) with BDP/FF (OR=1.44; p<0.001). Partial remission was similar in the two groups: 420 patients (36.65%) with BDP/FF/G vs. 396 patients (34.59%) with BDP/FF (OR=1.10; p=0.283). <bold>Conclusion:</bold> Clinical remission can be achieved in a substantial proportion of patients with uncontrolled asthma by inhalation therapy alone. The likelihood of complete remission is significantly higher with triple therapy BDP/FF/G vs. dual therapy BDP/FF. <table-wrap><object-id>erj;66/suppl_69/PA482/TB1</object-id><object-id>T1</object-id><object-id>TB1</object-id><table><colgroup><col></col><col></col><col></col><col></col><col></col></colgroup><tbody><tr><td></td><td>BDP/FF (n.1145)</td><td>BDP/FF/G (n.1146)</td><td>OR (95%CI)</td><td>p-value</td></tr><tr><td>Complete Remission</td><td>260 (22.71%)</td><td>338 (29.49%)</td><td>1.44 (1.19, 1.73)</td><td><0.001</td></tr><tr><td>Partial Remission</td><td>396 (34.59%)</td><td>420 (36.65%)</td><td>1.10 (0.93, 1.30)</td><td>0.283</td></tr></tbody></table></table-wrap>
Read moreDevelopment and Current Situation of Comprehensive Check-up in Taiwan
The history of comprehensive health check-ups in Taiwan dates back to 1956, when the National Taiwan University Hospital initiated a six-day in-hospital health check-up service. Initially, only the wealthy and influential could afford such services.
Read moreLifestyle Risk Factors That Increase Chances of Developing Oral Cancer: Up to Date Review
Oral cancer is on the 6th most common cause of malignancies of the world. With higher prevention strategies, the 5‑year survival rate of oral cancer is lower than 50% in some countries. Several risk factors that are linked with lifestyle behaviors have been identified in the occurrence of oral cancers. 2.Methods: Multiple database from 2014 to mid 2024. Applying filters were used to identify systematic reviews and meta-analyses, which investigated oral cancer incidence and risk factors. All published articles related to ″behavior risk factors in oral cancer″ were included in this review. 3.Results: The utilization of tobacco has reached the proportions of a global epidemic; alcohol association even raises the risk of developing oral cancer. In recent studies, there has been an association between smoking and a higher HPV infection. In addition, Candida albicans disrupt the metabolism of epithelial cells, so they can evolve from leukoplakia to dysplasia or even carcinoma leading to association of chronic inflammation. Also a persisting chronic inflammation with the association of one more risk factors from above can lead to an increase chance of developing oral cancer. 4.Conclusion: Most oral cancer are due to behavior habits, the main risk factors in oral cancer are smoking, alcohol consumption and the presence of HPV. ). Improving lifestyle changes should be one of the goals in every patient’s life. In addition, different strategy of public health information should be promoted in order to consider giving up smoking and excessive drinking of alcohol. A change in diet is also necessary. Therefore, public health campaigns are essential in determining a prevention of behavior lifestyle habits especially in younger adults because they represent the future adults.
Read moreCardiopulmonary Risk Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Triple Therapy: A Number Needed to Treat Post Hoc Analysis of the ETHOS Trial
Abstract Rationale: The number needed to treat (NNT) describes the absolute effect of an intervention over a period of time and can aid clinical decision making. The relative benefits of a triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) therapy budesonide/glycopyrrolate/formoterol fumarate (BGF) over the dual LAMA/LABA therapy of glycopyrrolate/formoterol fumarate (GFF) for a range of cardiopulmonary endpoints have been reported. In the current analyses, we estimate the NNTs for these endpoints. Methods: In the ETHOS randomized controlled trial, patients with moderate-to-very severe COPD and a history of exacerbations were randomly allocated to one of four treatment arms including twice-daily BGF 320/18/9.6μg, and GFF 18/9.6µg administered via a metered dose inhaler. The annualized NNT for the comparison of BGF with GFF for time to first cardiac AE (which included any adverse event (AE) within the cardiac disorders System Organ Class [SOC]), time to major adverse cardiac event (MACE), and time to a composite endpoint of severe cardiopulmonary events (MACE, severe COPD exacerbation leading to hospitalization, or death due to a respiratory cause) were calculated using a Kaplan-Meier approach. Endpoints were not adjusted for multiplicity and the analyses are considered exploratory in nature. Results: Over 8500 patients received treatment and were included in the analyses. Approximately 70% of patients in each treatment group had at least one cardiovascular risk factor at baseline. BGF had beneficial effects on time to first events for all endpoints considered in the analyses. The annualized NNTs for BGF versus GFF were NNT = 27 [95% CIs: 21-45] for cardiac AE, NNT = 118 [95% CIs: 70-NC] for MACE, and NNT = 37 [95% CIs: 22-148] for severe cardiopulmonary events, respectively. Conclusion: In the ETHOS trial of patients with moderate/very severe COPD, estimated annualized NNTs for a range of cardiopulmonary events comparing BGF with LAMA/LABA treatment suggest that triple therapy with BGF improves outcomes beyond the respiratory system alone.
Read moreA phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.
Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies.
SummaryWhat is this summary about?● This is a plain language summary of two articles originally published in The New England Journal of Medicine and The Lancet Respiratory Medicine. These articles presented the results of GALATHEA and TERRANOVA, two clinical studies that took place across 41 countries. ○ GALATHEA and TERRANOVA measured how patients' COPD changed from before their first benralizumab (10, 30, or 100 mg) injection, to after 56 weeks of treatment. ○ In both studies, benralizumab was compared with placebo. ○ To see whether benralizumab treatment would benefit any particular patients included in these studies, researchers carried out an additional analysis following the main studies of GALATHEA and TERRANOVA.
Read more